Association between weight loss and death in patients with malignant melanoma: A retrospective study of 28 cases.
cachexia
malignant melanoma
overall survival
weight loss
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
27 Sep 2023
27 Sep 2023
Historique:
revised:
12
09
2023
received:
08
04
2023
accepted:
12
09
2023
medline:
27
9
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
aheadofprint
Résumé
Malignant melanoma (MM) is often associated with a poor prognosis due to metastasis and cancer death. The monitoring of prognostic factors is of vital importance, and among these factors, elevated lactate dehydrogenase (LDH) should be closely observed during the disease course. Important factors for predicting the survival of MM patients include tumor thickness, ulceration, the number of lymph node metastases, metastatic lesions, and the sites of metastasis. Weight loss is not generally included in the prognostic factors of MM, but it is monitored in other cancers, such as lung cancer and gastrointestinal cancer. The objective of this study was to investigate the association between weight loss and MM prognosis. Using data from MM patients who had been treated at our institution, we assessed the prognoses of two groups: weight loss of at least 5% body weight or weight loss not exceeding 5% body weight within a 12-month period. As a result, a higher mortality rate was found for the former group. Furthermore, the loss of at least 5% of body weight within a month was found to almost always adversely affect the patient's prognosis. The present study indicates that there may be an association between MM prognosis and weight loss of at least 5% within a year, and body weight could potentially serve as an informative factor for MM survival.
Identifiants
pubmed: 37753543
doi: 10.1111/1346-8138.16982
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 Japanese Dermatological Association.
Références
Homsi J, Kashani-Sabet M, Messina J, Daud A. Cutaneous melanoma: prognostic factors. Cancer Control. 2005;12:223-229.
Mytelka D, Li L, Benoit K. Post-diagnosis weight loss as a prognostic factor in non-small cell lung cancer. J Cachexia Sarcopenia Muscle. 2018;9:86-92.
O'Gorman P, McMillan D, McArdle C. Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer. 2000;37:36-40.
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489-495.
Biswas AK, Acharyya S. Understanding cachexia in the context of metastatic progression. Nat Rev Cancer. 2020;20:274-284.
McMillan DC, Watson WS, O'Gorman P, Preston T, Scott HR, McArdle CS. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. 2001;39:210-213.
Simmons CP, Koinis F, Fallon MT, Fearon KC, Bowden J, Solheim TS, et al. Prognosis in advanced lung cancer-a prospective study examining key clinicopathological factors. Lung Cancer. 2015;88:304-309.
Shang L, Hattori M, Fleming G, Jaskowiak N, Hedeker D, Olopade OI, et al. Impact of post-diagnosis weight change on survival outcomes in black and white breast cancer patients. Breast Cancer Res. 2021;23:18.
Lieffers JR, Mourtzakis M, Hall KD, McCargar LJ, Prado CM, Baracos VE. A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. Am J Clin Nutr. 2009;89:1173-1179.
Ahmed I. Malignant melanoma: prognostic indicators. Mayo Clin Proc. 1997;72:356-361.